9 Meters Biopharma, Inc. (NMTR): Price and Financial Metrics

9 Meters Biopharma, Inc. (NMTR): $0.07

0.05 (-42.97%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add NMTR to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#200 of 379

in industry

NMTR Price/Volume Stats

Current price $0.07 52-week high $6.56
Prev. close $0.13 52-week low $0.07
Day low $0.07 Volume 9,957,800
Day high $0.11 Avg. volume 315,915
50-day MA $0.64 Dividend yield N/A
200-day MA $1.54 Market Cap 1.04M

NMTR Stock Price Chart Interactive Chart >


9 Meters Biopharma, Inc. (NMTR) Company Bio


9 Meters Biopharma, Inc. operates as a biotechnological company. The Company focuses on development of drugs and treatments for rare disorders and unmet needs. 9 Meters Biopharma serves customers worldwide.


NMTR Latest News Stream


Event/Time News Detail
Loading, please wait...

NMTR Latest Social Stream


Loading social stream, please wait...

View Full NMTR Social Stream

Latest NMTR News From Around the Web

Below are the latest news stories about 9 METERS BIOPHARMA INC that investors may wish to consider to help them evaluate NMTR as an investment opportunity.

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.

Yahoo | May 30, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.

Yahoo | May 15, 2023

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity.

Yahoo | April 5, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022.

Yahoo | March 28, 2023

9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock

Yahoo | March 15, 2023

Read More 'NMTR' Stories Here

NMTR Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -88.75%
3-year -99.68%
5-year N/A
YTD N/A
2023 0.00%
2022 -93.56%
2021 13.93%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!